ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2018

Jan 30, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2018-01-25

Reporting Person: Li Zhen (Snr. VP, Chemistry and Mfg)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	167200	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$16.33	2024-03-27	Common Stock (60000)		Direct
Stock Option	$5.45	2024-12-10	Common Stock (47500)		Direct
Stock Option	$6.15	2026-01-01	Common Stock (50000)		Direct

Footnotes

F1: Includes a total of 150,000 shares underlying restricted stock units. 85,000 of these restricted stock units will vest in January 2019, and the remaining 65,000 will vest in 4 equal annual tranches beginning in January 2019.

F2: Option vests and becomes exercisable over a four year period from date of grant.